Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lyra Therapeutics Inc LYRA

Healthcare
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that... see more

Recent & Breaking News (NDAQ:LYRA)

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

PR Newswire April 25, 2022

Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022

PR Newswire April 21, 2022

Lyra Therapeutics Announces Closing of $100.5 Million Private Placement

PR Newswire April 13, 2022

Lyra Therapeutics Announces $100.5 Million Private Placement

PR Newswire April 8, 2022

Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

PR Newswire March 9, 2022

Lyra Therapeutics Appoints Jim Tobin to Board of Directors

PR Newswire March 7, 2022

Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

PR Newswire February 28, 2022

Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman

PR Newswire February 17, 2022

Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients

PR Newswire January 24, 2022

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

PR Newswire November 11, 2021

Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

PR Newswire November 9, 2021

Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9

PR Newswire November 2, 2021

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society

PR Newswire October 4, 2021

Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

GlobeNewswire September 21, 2021

Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data

GlobeNewswire September 20, 2021

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

GlobeNewswire September 13, 2021

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo(TM) Technology Platform in the American Journal of Rhinology & Allergy

GlobeNewswire September 9, 2021

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

GlobeNewswire August 17, 2021

Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments

GlobeNewswire August 9, 2021